When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Trending Investment Opportunities
Conifer Holdings
The Trade: Conifer Holdings, Inc. CNFR Director Joseph Sarafa acquired a total of 50000 shares at an average price of $2.68. To acquire these shares, it cost $133,889.98.
What’s Happening: The company’s shares have dropped around 12% year-to-date.
What Conifer Holdings Does: Conifer Holdings is an insurance company. The company's operating segment includes Commercial Lines; Personal Lines; Under-writing; Wholesale Agency and Corporate. It generates maximum revenue from the Under-writing segment.
PEDEVCO
The Trade: PEDEVCO Corp. PED CEO Simon Kukes acquired a total of 99126 shares shares at an average price of $1.42. The insider spent $140,763.69 to buy those shares.
What’s Happening: Pedevco, last month, reported Q2 EPS of $0.00, versus a year-ago loss of $0.04 per share.
What PEDEVCO Does: PEDEVCO is an energy company. It is engaged in the acquisition, exploration, development, and production of oil and natural gas shale plays in the Denver-Julesberg Basin (D-J Basin) in Colorado.
Hill International
The Trade: Hill International, Inc. HIL Director Paul Evans acquired a total of 10725 shares at an average price of $2.04. To acquire these shares, it cost $21,857.55.
What’s Happening: Hill International recently secured a five-year IDIQ contract to provide construction management and inspection (CMI) services to the Maryland Aviation Administration (MAA) until 2026.
What Hill International Does: Hill International provides project and construction management, and other consulting services for the buildings, transportation, environmental, energy, and industrial markets.
InMed Pharmaceuticals
The Trade: InMed Pharmaceuticals Inc. INM President and CEO Eric A Adams acquired a total of 11400 shares at an average price of $1.75. To acquire these shares, it cost $19,984.20.
What’s Happening: InMed Pharmaceuticals recently reported an FY21 EPS loss of $(1.52) narrower than $(1.71) posted a year ago.
What InMed Pharmaceuticals Does: InMed Pharmaceuticals is a Canada based clinical-stage biopharmaceutical company.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.